DexCom, Inc. $DXCM Stock Bought by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 5.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,271,194 shares of the medical device company’s stock after acquiring an additional 66,641 shares during the period. DexCom accounts for approximately 1.2% of Stephens Investment Management Group LLC’s portfolio, making the stock its 18th biggest position. Stephens Investment Management Group LLC owned about 0.34% of DexCom worth $109,691,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Harbour Wealth Management Group Inc. grew its position in DexCom by 9.2% in the third quarter. Harbour Wealth Management Group Inc. now owns 8,019 shares of the medical device company’s stock worth $692,000 after acquiring an additional 675 shares in the last quarter. Composition Wealth LLC bought a new stake in DexCom during the 3rd quarter valued at about $226,000. Global Retirement Partners LLC grew its stake in DexCom by 22.0% in the third quarter. Global Retirement Partners LLC now owns 25,358 shares of the medical device company’s stock worth $2,188,000 after purchasing an additional 4,574 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its position in DexCom by 27.8% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 358,931 shares of the medical device company’s stock valued at $30,973,000 after purchasing an additional 78,026 shares during the period. Finally, HighTower Advisors LLC raised its position in shares of DexCom by 13.2% in the 3rd quarter. HighTower Advisors LLC now owns 120,646 shares of the medical device company’s stock worth $10,411,000 after acquiring an additional 14,066 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Up 0.6%

Shares of DXCM opened at $82.52 on Thursday. DexCom, Inc. has a fifty-two week low of $56.72 and a fifty-two week high of $92.59. The company has a market capitalization of $30.78 billion, a PE ratio of 32.36, a price-to-earnings-growth ratio of 1.36 and a beta of 1.45. The stock has a fifty day moving average of $84.10 and a two-hundred day moving average of $75.34. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.40 and a current ratio of 1.74.

DexCom (NASDAQ:DXCM – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.05. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The company’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.61 EPS. As a group, analysts forecast that DexCom, Inc. will post 2.68 EPS for the current year.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Wells Fargo & Company raised their target price on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Robert W. Baird set a $105.00 price objective on shares of DexCom and gave the stock an “outperform” rating in a research report on Friday, July 31st. Barclays raised their price target on DexCom from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Sanford C. Bernstein upped their price target on DexCom from $77.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Finally, Mizuho set a $100.00 target price on DexCom in a report on Tuesday, October 13th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $95.50.

Get Our Latest Stock Report on DexCom

Insider Activity

In other news, EVP Sadie Stern sold 2,565 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $88.37, for a total transaction of $226,669.05. Following the completion of the transaction, the executive vice president directly owned 126,043 shares in the company, valued at approximately $11,138,419.91. This represents a 1.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme M. Sylvain sold 3,638 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total transaction of $302,936.26. Following the transaction, the executive vice president directly owned 146,828 shares of the company’s stock, valued at approximately $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 22,822 shares of company stock valued at $1,920,193 over the last ninety days. 0.28% of the stock is owned by company insiders.

DexCom Company Profile

(Free Report)

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

Featured Articles

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.